Sanofi's Libtayo Succeeds In Basal Cell Carcinoma Study
Could Be First PD-1/PD-L1 Therapy For Most Common Form Of Skin Cancer
BCC is the second non-melanoma skin cancer for which Libtayo has demonstrated efficacy as the PD-1 inhibitor, which also recently impressed in a lung cancer study, is already approved for cutaneous squamous cell carcinoma.
You may also be interested in...
The company reported strong 33% revenue growth in Q1, despite softer Eylea sales from postponed treatments, progressed in oncology, and is moving an antibody cocktail for COVID-19 into clinical testing.
The anti-CD38 antibody will face an entrenched rival, J&J's Darzalex, for multiple myeloma.
Nine months after the US approval, the EU has followed suit and given a conditional approval for Sanofi and Regeneron’s IO Libtayo for a, so far, untreatable skin cancer.